To investigate the prognostic value of US in predicting musculoskeletal flares and Jaccoud's arthropathy (JA) in Systemic Lupus Erythematosus (SLE).
Introduction

Musculoskeletal (MS) complaints are very common in Systemic Lupus Erythematosus
(SLE) affecting 70-95% of patients (1) (2) (3) . They represent the heralding symptom in 60-80% of cases and are reported in up to 60% of disease flares (3, 4) . Inflammatory MS manifestations are described as a major cause of pain and compromised hand function, interfering with daily activities in 73% of SLE patients and causing low productivity or work disability in 49% and 17% of them, respectively (5) (6) (7) (8) . In particular, impairment of patients' health related quality of life (HRQoL) is mostly associated with MS flares (9, 10) . Inflammatory joint involvement in SLE primarily affects the hands and clinically occurs as transient and migratory arthralgia (30-50%), or fleeting (25-40%) or persistent (10-15%) arthritis but tenosynovitis could also be present (11) . SLE arthritis is often classified as non-deforming and non-erosive (NDNE) on X-ray (12) , but hands and feet deformities may arise in 5-15% of cases as hallmarks of Jaccoud's Arthropathy (JA) (12, 13) . Radiographic erosions may be detected in less than 5% of patients showing persistent arthritis, sometimes deformities, high prevalence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (aCCP), thus referred as rhupus syndrome (RS) to indicate an overlap between Rheumatoid Arthritis (RA) and SLE (12, 14) . This classification has been recently questioned by ultrasound (US) studies that showed an unexpected burden of erosive damage in up to 41% of patients as well as a surprisingly high prevalence of synovitis (25-94%) and tenosynovitis (28-65%) (15) .. These data challenge the belief that lupus arthritis is a benign entity and suggest that the burden of joint damage in SLE may be underestimated (15, 16) , Identifying factors associated with MS flares and development of joint damage, such as deformities, would help preventing a major cause of disability for SLE patients. In particular, unveiling the progression and predictive values of synovitis, tenosynovitis and erosions detected by high-resolution US, which prognostic properties have not been addressed by longitudinal studies, can be crucial in facilitating targeted therapies and measuring response (15, 16) . US was proved to be more sensitive than clinical examination in detecting joint ad tendon inflammation (17) (18) (19) (20) (21) , which even subclinical has been reported as predictive of MS flare (22) and responsible for future development of JA (23) . This prospective study was planned with the aim to clarify whether and which high-resolution US findings are associated with an increased risk of MS flares and JA. As secondary aims we would estimate their prevalence and incidence, highlighting their impact on patients HRQoL and identifying other relevant clinical or serological predictive factors.
Patients and methods
Study design
Ninety-four consecutive Caucasian patients fulfilling at least 4 of the 1997 ACR criteria for SLE (24) were recruited between January 2010 and April 2010 in a 5-year prospective study.
Follow-up visits were scheduled every 6 months (figure 1). In order to assure complete capturing of clinically significant data, patients were asked to refer to the clinic in case of symptoms suggestive of disease flare or drug adverse event and both patients and healthy controls were solicited by phone call to attend the scheduled visits. Those who failed to attend the scheduled visits were excluded from the study in order to minimize data loss.
Inclusion criteria were: a) past or present joint and/or tendons inflammatory involvement, b)
having not taken NSAIDs in the 5 days prior to baseline, c) having been on stable corticosteroids dose over previous 4 weeks, d) having been on stable antimalarial and immunosuppressive therapy over previous 3 months. Exclusion criteria were: i) RS defined by the presence of X-ray erosions or fulfilment of both SLE and RA classification criteria (25) , ii) hand and feet deformities, iii) avascular necrosis or iv) myositis. Sixty age-and gender-matched volunteers were recruited from healthy hospital staff as controls.
Ethical approval for the study was obtained from the local Ethics Committee (references 111/10/CE and 224/11/CE) and all participants gave their written informed consent.
2.2.Study outcomes
The British Isles Lupus Assessment Group (BILAG) 2004 disease activity index is sensitive to change and suitable for use in longitudinal studies of SLE if the outcome of interest is worsening of disease activity (26) . MS flares were defined as any increase in activity to grade A (severe) or B (moderate) in the MS-BILAG domain. Any increase in activity to grade C was defined as minimal change and not included in flare definition (26) .
Development of JA was defined as any increase (≥1) in JA index (table 1) calculated according to Spronk et al. (23) .
2.3.Clinical assessment
At every visits, patients and controls underwent detailed standardized joints and tendons examination according to EULAR recommendations (27) . A bilateral examination for tenderness and swelling of the following joints was performed: shoulder, elbow, wrist, metacarpophalangeal (MCP) , proximal inter-phalangeal (PIP) of the hand, knee, ankle and metatarsophalangeal (MTP).
Fixed or reducible MCP subluxation, ulnar drift, swan neck or boutonniere deformities of the fingers and Z thumbs were also evaluated. A bilateral examination for tenderness and swelling of the following tendons or group of tendons was performed: flexor pollicis longus tendon, flexor carpi radialis tendon, flexor digitorum tendons of the second, third, fourth and fifth fingers (at both common tendon sheath and finger tendon sheath level), extensor tendons of the first, second, third, fourth, fifth, and sixth compartments.
SLEDAI was used to assess global disease activity and BILAG was applied to evaluate disease activity in individual organ systems. A mean longitudinal MS-BILAG score was calculated by assigning at each visit result an additive numerical scoring scheme as follows: A = 12 (very active disease), B = 8 (moderate activity), C = 1 (mild stable disease) and D = 0 (inactive but previously involved) (28) . According to inclusion criteria no patient scored E (no current or previous disease activity). Cumulative organ damage was calculated using the ACR/Systemic Lupus International Collaborating Clinics Damage Index (SDI). Clinical assessment and indices calculation were performed by a trained rheumatologist blind to serologic, ultrasonographic and radiologic findings.
2.4.Serologic assessment
At baseline, each patient was tested for ANAs (IF Hep-2), anti-Ro/SSA, anti-La/SSB, anti-RNP, anti-Sm (ELISA; Normal Value (NV) <10 IU/dl), RF (ELISA; NV<14 IU/dl) anti-CCP (ELISA; NV<25 IU/dl) and HLA-DR1/DR4 status. Anti-dsDNA (Farr assay; NV<7 IU/dl), CRP (NV<0.5 mg/dl), C3 (NV 90-180 mg/dl) and C4 (NV 10-40 mg/dl) complement fraction levels was tested at baseline and prior to each follow-up visit. 
2.5.Ultrasound and radiographic assessment
2.6.Statistical analysis
The characteristics of interest were reported as mean ± standard deviation (S.D.) or median Stepwise Cox proportional hazard models were fitted with covariates with p<0.1 to predict outcomes. Specificity and sensitivity of predictive factors was calculated by mean of ROC curve.
Two-tailed p values less than 0.05 were considered significant. Relative Risk (RR) with 95%
Confidence Interval (CI) were calculated. Statistical analyses were performed using the software package MedCalc 15.0 (MedCalc Software, Mariakerke, Belgium).
Results
Study population
Eighty patients (76 female; age 45.5±13.2 years) and 48 healthy controls (42 female; age 49.6±11.6 years) completed the 5-year follow-up (Table 2) . Reasons for drop-out of 14 SLE patients and 12 healthy controls were: outmigration, change of address or phone number, withdrawal of consent and death. No major differences between groups were detected.
At baseline, 9/80 (11.2%) patients reported arthritis in the past month but only 7/80 (8. US detected a higher number of inflamed joints and tendons than clinical examination (supplementary file 1). US synovitis and tenosynovitis with GS≥2 and PD≥1 were more frequent in patients with higher MS-BILAG score, but were also detected in 5 out of 21 (23.8%) patients scoring C and were almost absent (1.9%) in those scoring D (Table 3 ). In particular, GS-synovitis≥2 was found in 25 (5.2%) out of 480 scanned joints (10 were not clinically tender or swollen) from 6/80 (7.5%) patients of whom 3 scored C on MS-BILAG. PD-synovitis≥1 was detected in 32/480 (6.7%) joints (11 without clinical synovitis), from 10/80 (12.5%) patients of whom 4 scored C on MS-BILAG. GS-tenosynovitis≥2 was found in 10 (0.5%) out of 1920 scanned tendon sites (8 were not clinically tender nor swollen) from 4/80 (5.0%) patients of whom 3 scored C on MS-BILAG.
PD-tenosynovitis≥1 was detected in 19/1920 (1.0%) tendon sites (13 with no sign of tenosynovitis) from 9/80 (11.2%) patients of whom 5 scored C and 1 scored D on MS-BILAG.
Considering US as the gold standard for joints and tendons assessment, a low sensitivity (31.6% for tendons, 65.6% for joints) with high specificity (96.7% for joints, 99.0% for tendons) of the clinical assessment was found. Baseline detection of US erosions was not associated with increased risk of MS-flare either at patient level nor at joint level.
Musculoskeletal flares at patient level
Musculoskeletal flares at joint level
Hand deformities
Five (6.2%) patients developed hand deformities ( 
US erosions
At final visit, new US erosions were revealed in 13/80 (16.3%) patients of whom 4 had US erosions at baseline, but none showed erosion on X-ray. Major accrual of US erosions was detected at second MCP level bilaterally (see supplementary file 3). The incidence of new US erosions was significantly higher (p=0.022) in SLE patients compared with healthy controls (n=1; 2.0%).
Patient Reported Outcomes
Patients who developed JA had worse results in both physical and mental health components of the SF36v2 than NDNE, and both scored worse than healthy controls (figure 5A), at the end of follow-up. In NDNE patients, SF36v2 mental and physical domains were mostly influenced by high MS-BILAG score (figure 5B) rather than by the evidence of US joint erosions ( figure 5C ). In particular, patients who scored ≥ C on MS-BILAG had statistically significant lower results in bodily pain (p=0.004) and global health (p=0.019) components of the SF36v2 questionnaire than patients who scored D.
Discussion
This study identified a risk profile for musculoskeletal flares and Jaccoud's deformities, reported the incidence of these two complications and depicted them as determinants of impaired HRQoL in a large prospectively followed-up and representative cohort of SLE patients with NDNE arthritis. Moreover, it provided valuable insights into the progression and predictive value of abnormalities detected by high-resolution US in SLE and supported previous observations highlighting that US is more accurate than physical examination in detecting joint and tendon inflammation in symptomatic SLE patients without clinical joint swelling or tendonitis (17) (18) (19) (20) (21) .
We firstly demonstrated that, although frequently detected in patients, baseline subclinical synovitis or tenosynovitis (GS=1 without PD signal) are also observed in healthy controls and had no prognostic or predictive value. However, the most significant and innovative finding to emerge from this study is that, after correction for the potential confounding effect of disease activity and treatment changes, a higher PD-synovitis score at baseline was independently predictive of MS flare within 24 months since US examination. The time-restricted effect of PD-synovitis score suggests that, rather than be a marker for a more aggressive (e.g. deforming) subtype of SLE arthritis, it recognized patients with residual or subclinical disease activity not detectable on clinical examination and, if not properly treated, at risk for flare. Therefore, this marker can help the clinician in the decision making process for starting or enhancing immunosuppressive therapy in order to prevent MS flare. In this scenario, performing US could be useful in clinical practice for symptomatic patients without synovitis on physical examination, scoring C on MS-BILAG, who do not deserve increased immunosuppression for high disease activity in other organs or systems.
Along with this novel observation, we longitudinally estimated the incidence and prevalence of JA as 1.2 per 100 patient-year and 6.2%, respectively. To the best of our knowledge this is the first report on the incidence of JA in SLE patients, whereas previous cross-sectional study reported the prevalence of Jaccoud's deformities as 3.5-13.3% (13, 35) . The risk profile for development of JA was characterized by prolonged even subclinical joint and tendon inflammation, according to longitudinal MS-BILAG activity score, and longer disease duration. Baseline US findings were not associated with development of JA probably because the long time needed for appearance of deformities and the transient nature of joint and tendon inflammation; the latter is supported by the relatively low incidence and severity of inflammatory abnormalities detected by US (18) and histopathology (36) in these patients. Subclinical inflammation in joints and tendons was addressed as responsible for accrual of soft tissue damage resulting in JA (36, 37) , however it cannot satisfactorily explain why only a relatively small proportion of patients develops deformities.
Previous cross-sectional studies (13, 18, 23, 35) identified longer disease duration as a risk factors for JA, but the mechanisms underlying this association are unclear. Higher cumulative dose of corticosteroids may be partly responsible for impaired soft tissue healing and remodeling in susceptible individuals (38, 39) resulting in joint laxity and loss of articular stabilizing mechanisms.
Although we did not look at cumulative steroids dose in our cohort, patients developing Jaccoud's deformities were all treated with long-standing low dose steroids and lack in immunosuppressants.
In light of these observations we would suggest to consider JA as a late complication of NDNE, consequent to treatment failure, and not a distinct subtype of SLE arthritis. Further prospective studies are needed to evaluate the potential effect of targeted strategies, based on ultrasonographic tight control of MS disease activity and steroid-sparing agents, in preventing development of hand deformities.
We also showed that the burden of US erosions slightly progressed over time in patients with NDNE but, unlike erosions seen in RA (40), they were not predictive of deformities or accrual of erosive damage. Moreover, it is noteworthy that US erosions were not a cause of worse HRQoL in NDNE patients whereas active MS activity and Jaccoud's deformities resulted major determinants for low HRQoL. In the light of this evidence a patient should not be classified as suffering from RS relying solely on isolated US findings. In the absence of X-rays erosions, RAlike synovitis and persistently high anti-CCP and RF should raise suspicion of pre-radiographic form of RS and must suggest a more aggressive treatment (41).
This study have some limitations. First, although we made an effort in order to minimize the effect of treatment confounding factors, further studies based on targeted therapy in naïve patients are needed to confirm these data. Nevertheless, this could be particularly difficult as lupus is a systemic disease and patients need different therapeutic approaches tailored according to severity of symptoms and occurrence of life-threatening manifestations. Second, this study was not specifically designed to assess the effect of different MS manifestation on HRQoL, thus our results should be confirmed by future studies. Third, we recorded a 14.8% and 20.0% drop-out rate in SLE patients and healthy controls, respectively. However, in observational studies conducted over a lengthy period of time a high drop-out rate is to be expected and, conventionally, a 20% drop-out rate is regarded as acceptable (42) . Moreover, drop-out rates were comparable in the two groups and by assuring the complete capturing of clinically significant data we minimized concerns in interpretation of study results.
In conclusion, high-resolution US could be an effective response to the unmet need for a more sensitive and specific tool for assessing joint and tendons in SLE patients, especially those scoring C on MS-BILAG complaining of inflammatory joint pain but without clinical synovitis or tenosynovitis. US could be clinically useful in order to identify those patients at risk for MS flare and consequently institute the most appropriate treatment to prevent hand deformities and deterioration of HRQoL. Further studies combining histopathology and imaging tools, including CT and MRI, are needed to shed some light on their potential clinical implications and therapeutic targets for preventing MS inflammation and damage in SLE patients. SF, social functioning; VT, vitality. NDNE, non-deforming non-erosive.
